RESEARCH

Area 1
area1_iis-laprincesa

AETIOPATHOGENIC, CELLULAR AND MOLECULAR MECHANISMS IN INFLAMMATORY AND AUTOIMMUNE DISEASES.

Area 1 is made up of 10 lines and 24 research groups, the main aims of which are: deciphering the cellular and molecular mechanisms that control crucial biological processes in autoimmune and inflammatory diseases; identifying molecular entities and cellular processes that may serve as targets for the action of new drugs for inflammatory/autoimmune-based diseases; implementing advanced experimental techniques and new animal models of diseases allowing improvements to basic studies to analyse their pathophysiological mechanisms, and to conduct pre-clinical studies and promote translational research by promoting interaction between basic and clinical groups.

Miembros

area1-linea1-g1_dr-sanchez-madrid

Coordinator

Dr Francisco Sánchez Madrid

Area 2
area2_iis-laprincesa

TRANSLATIONAL NEUROSCIENCE.

Area 2 is made up of 6 research lines, with one group per line. Its general objectives are: the design, synthesis and characterisation of new compounds with potential neuroprotection effects in neurodegenerative disease and cerebrovascular accidents; the search for biomarkers for early diagnosis, the study of disease progression and treatment response; the characterisation of drugs in preclinical trials in animal models and in human clinical trials; and the expansion of knowledge of affective disorders in the population, studying risk factors, clinical evolution and treatment response, with the aim of improving the population’s mental health.

Miembros

area-2_Linea1_G28_Dr-Garcia_Garcia

Coordinator

Dr José Luis Ayuso Mateos

Area 3
area3_iis-laprincesa

ADVANCED THERAPY AND PERSONALISED MEDICINE.

Area 3 is made up of 8 research lines and 18 research groups. Among their general objectives are: the identification of biomarkers that allow prognosis and/or treatment response to be predicted when treating inflammatory, infectious or tumour-based diseases; optimisation of biological treatments through identification of biomarkers that predict treatment response; the identification of new drugs and/or treatment targets; and the search for new treatment and improvements in treatment efficacy and safety and management of treatment effects on patient quality of life.

Miembros

area3_dr-Isidoro_Gonzalez_alvaro

Coordinator

Dr Isidoro González Álvaro